🇺🇸 FDA
Pipeline program

Transepicardial with Transseptal CD 133+ Implantation

LB.02.01/VII/086/KEP.007.EV

Approved mab completed

Quick answer

Transepicardial with Transseptal CD 133+ Implantation for Coronary Artery Disease is a Approved program (mab) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Coronary Artery Disease
Phase
Approved
Modality
mab
Status
completed

Clinical trials